摘要:
Methods of inhibiting phosphatidylinositol 3-kinase delta isoform (PI3Knull) activity, and methods of treating diseases, such as disorders of immunity and inflammation, in which PI3Knull plays a role in leukocyte function are disclosed. Preferably, the methods employ active agents that selectively inhibit PI3Knull, while not significantly inhibiting activity of other PI3K isoforms. Compounds are provided that inhibit PI3Knull activity, including compounds that selectively inhibit PI3Knull activity. Methods of using PI3Knull inhibitory compounds to inhibit cancer cell growth or proliferation are also provided. Accordingly, the invention provides methods of using PI3Knull inhibitory compounds to inhibit PI3Knull-mediated processes in vitro and in vivo.
摘要:
The present invention relates to compounds of the formula 1 wherein R1, R2, R3, R4, R5, R6, R7, R8, A, X and Y are defined as in the specification, to pharmaceutical compositions containing them and to their medicinal use. The compounds of the invention are useful in the treatment or alleviation of inflammation and other inflammation associated disorders, such as arthritis, colon cancer, and Alzheimer's disease in mammals, preferably humans, dogs, cats and livestock animals.
摘要:
Compounds of Formula I are useful for inhibiting serine protease enzymes, such as TF/factor VIIa, factor Xa, thrombin and kallikrein and have improved pharmacokinetic properties. These compounds may be used in methods of preventing and/or treating clotting disorders. 1
摘要:
Described herein are compounds that are useful as protein kinase inhibitors having the formula: 1 wherein Z1 and Z2 are each independently nitrogen or CH and Ring A, TmR1, QR2, UnR3, and Sp are as described in the specification. The compounds are especially useful as inhibitors of ERK2 and for treating diseases in mammals that are alleviated by a protein kinase inhibitor, particularly diseases such as cancer, inflammatory disorders, restenosis, diabetes, and cardiovascular disease.
摘要翻译:本文描述了可用作具有下式的蛋白激酶抑制剂的化合物:其中Z 1和Z 2各自独立地为氮或CH,环A,TmR 1,Q 2,R un R 3, 和Sp如说明书中所述。 该化合物特别可用作ERK2的抑制剂,并且用于治疗由蛋白激酶抑制剂,特别是癌症,炎性疾病,再狭窄,糖尿病和心血管疾病等疾病缓解的哺乳动物疾病。
摘要:
This invention concerns HIV replication inhibitors of formula (I) the N-oxides, the pharmaceutically acceptable addition salts, the quaternary amines and the stereochemically isomeric forms thereof, wherein the ring containing -a1nulla2-a3nulla4- and -b1nullb2-b3nullb4- represents pheynl, pyridyl, pyrimidinyl, pirazinyl, pyridazinyl;n is 0 to 5; m is 1 to 4; R1 is hydrogen; aryl; formyl; C1-6alkylcarbonyl; C1-6alkyl; C1-6alkyloxycarbonyl, substituted C1-6alkyl, C1-6alkylcarbonyl; R2 is hydroxy, halo, optionally substituted C1-6alkyl, C3-7cycloalkyl, optionally substituted C2-6alkenyl, optionally substituted C2-6alkynyl, C1-6alkyloxy, C1-6alkyloxycarbonyl, carboxyl, cyano, nitro, amino, mono- or di(C1-6alkyl)amino, polyhalomethyl, polyhalomethyloxy, polyhalomethylthio, nullS(nullO)pR6, nullNHnullS(nullO)pR6, nullC(nullO)R6, nullNHC(nullO)H, nullC(nullO)NHNHnull2null, nullNHC(nullO)R6, nullC(nullNH)R6 or a 5-membered hetrocycl; X1 is nullNR5null, nullNHnullNHnull, nullNnullNnull, nullOnull, nullC(nullO)null, C1-4alkanediyl, nullCHOHnull, nullSnull, nullS(nullO)pnull, nullX2nullC1-4alkanediyl- or nullC1-4alkanediyl-X2null; R3 is NHR13, NR13R14; nullC(nullO)nullNHR13; nullC(nullO)nullNR13R14; nullC(nullO)nullR15; nullCHnullNnullNHnullC(nullO)nullR16; substituted C1-6alkyl; optionally substituted C1-6alkyloxyC1-6alkyl; substituted C2-6alkenyl; substituted C2-6alkynyl; substituted C2-6alkylenyl; C1-6alkyl substituted with hydroxy and a second substituent; nullC(nullNnullOnullR8)nullC1-4alkyl; R7; or nullX3nullR7; R4 is halo, hydroxy, C1-6alkyl, C3-7cycloalkyl, C1-6alkyloxy, cyano, nitro, polyhaloC1-6alkyl, polyhaloC1-6alkyloxy, aminocarbonyl, C1-6alkyloxycarbonyl, C1-6alkylcarbonyl, formyl, amino, mono- or di(C1-4alkyl) amino; their use as a medicine, their processes for preparation and pharmaceutical compositions comprising them. 1
摘要翻译:本发明涉及式(I)的N-复合抑制剂,其N-氧化物,药学上可接受的加成盐,季胺及其立体化学异构形式,其中含-a 1 = a 2 -a 3 n = 0〜5; b 1 = b 2 -b 3 = b 4 - 表示吡啶基,吡啶基,嘧啶基,吡嗪基,哒嗪基; n为0〜5; m为1〜4; R 1是氢; 芳基; 甲酰基 C 1-6烷基羰基; C 1-6烷基; C 1-6烷氧基羰基,取代的C 1-6烷基,C 1-6烷基羰基; R 2是羟基,卤素,任选取代的C 1-6烷基,C 3-7环烷基,任选取代的C 2-6烯基,任选取代的C 2-6炔基,C 1-6烷氧基,C 1-6烷氧基羰基,羧基,氰基,硝基,氨基,单或 (C 1-6烷基)氨基,多卤甲基,多卤代甲氧基,多卤甲硫基,-S(= O)pR 6,-NH-S(= O)p R 6,-C(= O)R 6, NHC(= O)H,-C(= O)NHNH 2,-NHC(= O)R 6,-C(= NH)R 6或5元环庚烯; X1是-NR5 - , - NH-NH-,-N = N-,-O - , - C(= O) - ,C1-4烷二基,-CHOH-,-S-,-S(= O )p-,-X2-C1-4烷二基或-C1-4烷二基X2-; R 3是NHR 13,NR 13 R 14; -C(= O)-NHR 13; -C(= O)-NR 13 R 14; -C(= O)-R 15; -CH = N-NH-C(= O)-R 16; 取代的C 1-6烷基; 任选取代的C 1-6烷氧基C 1-6烷基; 取代的C 2-6烯基; 取代的C 2-6炔基; 取代的C2-6亚烷基; C
摘要:
Compounds and their use as pharmaceuticals particularly as Raf kinase inhibitors for the treatment of neurotraumatic diseases, cancer, chronic neurodegeneration, pain, migraine and cardiac hypertrophy.
摘要:
A method is provided for using compounds that exhibit combined activities as 5-HT1A active agents and selective serotonin reuptake inhibitors (SSRI's) to treat sexual dysfunction, particularly premature ejaculation, on an as-needed basis shortly before sexual activity.
摘要:
Compounds and their use as pharmaceuticals particularly as Raf kinase inhibitors for the treatment of neurotraumatic diseases, cancer, chronic neurodegeneration, pain, migraine or cardiac hypertrophy.
摘要:
The present invention relates to novel pyridazinone derivatives of the general formula (I) 1 wherein A is A1 or A2; 2 R is unsubstituted or at least monosubstituted C1-C10-alkyl, aryl, aryl-(C1-C10-alkyl)-, heteroaryl, heteroaryl-(C1-C10-alkyl)-, heterocyclyl, heterocyclyl-(C1-C10-alkyl)-, C3-C10-cycloalkyl, polycycloalkyl, C2-C10-alkenyl or C2-C10-alkinyl and Ar is unsubstituted or at least monosubstituted aryl or heteroaryl.
摘要:
This invention relates to pyridazine derivatives represented by the formula (1): 1 wherein R1 represents a (substituted) aryl group, R2 represents a phenyl group substituted at 4-position by a lower alkoxyl group or a lower alkylthio group, R3 represents a lower alkoxyl group, a halogenated lower alkyl group, a lower cycloalkyl group, a (subsituted) aryl group, a (substituted) aryloxy group, a (substituted) nitrogen-containing heterocyclic ring residue, a (substituted) aminocarbonyl group or a lower alkylcarbonyl group, A represents a single bond, a lower alkylene group or a lower alkenylene group, X represents O or S, and the dashed line indicates that the carbon-carbon bond between the 4-position and the 5-position is a single bond or a double bond, or salts thereof; and also to medicines containing them as effective ingredients. These compounds have excellent inhibitory activity against interleukin-1null production, and are useful as preventives and therapeutics for immune system diseases, inflammatory diseases, ischemic diseases and the like.